Essential thrombocythaemia (ET; primary/essential thrombocytosis)
Myeloproliferative neoplasm · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Clonal MPN with sustained platelet count >450 x10^9/L (often >600-1000), driven by JAK2, CALR or MPL mutations. Risk is both thrombosis and (with extreme counts) bleeding from acquired von Willebrand syndrome. Exclude reactive thrombocytosis first. ED role: risk-stratify, start aspirin in most, treat thrombosis, refer.
Red flags
- Acute thrombosis (stroke, MI, DVT/PE, splanchnic vein)
- Microvascular: erythromelalgia, visual/neuro transient symptoms
- Bleeding with platelet count >1000-1500 (acquired von Willebrand syndrome)
- Progressive splenomegaly / cytopenias (transformation to myelofibrosis)
Assessment
Differential diagnosis
- Reactive/secondary thrombocytosis (infection, inflammation, iron deficiency, post-splenectomy, malignancy, bleeding)
- Other MPN (PV, early myelofibrosis, CML)
- Myelodysplastic/myeloproliferative overlap (e.g. MDS/MPN-RS-T)
Investigations
- FBC + film (large platelets, confirm sustained count on repeat)
- JAK2 V617F; if negative CALR and MPL mutation analysis
- CRP/ESR, ferritin (exclude reactive causes/iron deficiency)
- BCR-ABL1 to exclude CML
- Von Willebrand screen (ristocetin cofactor) if platelets very high (>1000-1500) and bleeding
- Bone marrow biopsy (megakaryocyte morphology) per haematology
Management
- Confirm true sustained thrombocytosis and exclude reactive causes (treat the cause if reactive)
- Assess thrombotic/haemorrhagic risk (age >60, prior thrombosis, JAK2 positive, cardiovascular risk, platelet >1500)
- Start low-dose aspirin for most (vasomotor symptoms, JAK2-positive, CV risk) - but HOLD if acquired vWS/active bleeding until corrected
- Treat any acute thrombosis per standard pathway
- High-risk (age >60 or prior thrombosis): start cytoreduction (hydroxycarbamide first-line)
- Extreme thrombocytosis with bleeding: check/treat acquired von Willebrand (avoid aspirin; cytoreduce urgently)
- Manage cardiovascular risk factors
Drugs & doses
Aspirin 75-100 mg PO once daily (most patients; avoid if acquired vWS/bleeding)
Hydroxycarbamide (hydroxyurea) 15-20 mg/kg/day PO, titrate to platelets <400 x10^9/L (first-line high-risk) [verify local dose]
Anagrelide 0.5 mg PO twice daily, titrate (platelet-specific; caution cardiac, headache) [verify local dose]
Interferon alfa / peginterferon (younger patients, pregnancy) [verify local dose]
Plateletpheresis - reserved for acute life-threatening thrombosis/bleeding with extreme counts [verify local dose]
Disposition
Acute thrombosis/bleeding -> admit with haematology. Otherwise outpatient haematology referral for confirmation and risk-adapted therapy.
Complications & pitfalls
- Arterial/venous thrombosis
- Haemorrhage from acquired von Willebrand syndrome
- Transformation to myelofibrosis or AML (less common than PV)
- Pregnancy loss
Exam pearls
- Platelets >1000-1500 can cause BLEEDING not clotting via acquired vWS - do not reflexively give aspirin; check ristocetin cofactor
- Always exclude reactive thrombocytosis (iron deficiency, infection, malignancy) before labelling ET
- CALR-mutated ET has lower thrombotic risk than JAK2-mutated
- Erythromelalgia responds dramatically to aspirin
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.